Dapagliflozin: the outcome of it use as add-on therapy in real-life clinical setting

Authors

  • Umar Yousaf Raja Shifa International Hospital, Islamabad, Pakistan
  • Ponnusamy Saravanan George Elliot Hospital and University of Warwick, Coventry, UK

DOI:

https://doi.org/10.47391/JPMA.01-117

Abstract

Abstract

Dapagliflozin is the first novel SGLT2 inhibitor for the treatment of Type 2 diabetes. The aim of this study was to evaluate its effectiveness and safety in a real-life clinical setting. We analyze data from four hospitals on patients initiated on dapagliflozin. HbA1c, weight and daily insulin dosage was recorded at baseline and 6 months follow-up.229 patients received dapagliflozin. At baseline, mean HbA1c was 82mmol/mol(186) and mean weight was 102 kg(n=159).The average reduction in HbA1c at 6 months (n=121) was 13mmol/mol whereas the average reduction in weight(n=96) was 2kg.A mean reduction in daily insulin requirement(n=41) by 12 units(13%) at 6 months compared to baseline was noted. Nine patients developed candidiasis, eight developed UTI, five reported symptoms of thirst and five developed hypoglycaemia out of which four were on insulin and one on gliclazide. Ten patients discontinued(4%) dapagliflozin due to side effects. Our results confirm that dapagliflozin can be used safely and effectively in a real-life setting.

Keywords: Dapagliflozin, real world, SGLT2, Type 2 diabetes.

Continuous...

Published

2021-07-06